Annual Sale Flat 50% off on all reports. Limited Period Offer.

GLOBAL CANCER DIAGNOSTICS MARKET IS EXPECTED TO SHOW A BRISK GROWTH DURING THE FORECAST PERIOD

Mourya
Mourya
The report "GLOBAL CANCER DIAGNOSTICS MARKET”: Segmented By Type (Platform Based, Instrument Based, Biopsy Based, Endoscopy Based, Imaging Procedure and Others), By Application (Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Prostrate Cancer, Skin Cancer, Blood Cancer and Others), By End User (Hospitals, Clinics, Research Institutes, Laboratories and Others) & By Geography (Asia Pacific, North America, Europe, Middle East & Africa, South America), By Company Profile, Forecast (USD Billion) And Estimation 2018-2024. Cancer diagnostic market size is expected to be $XX billion by 2024 from $XX billion in 2017 at a CAGR of XX%. Cancer diagnostic market is the one, which is facing many challenges. The main factors are an early diagnosis of the disease and expensive diagnostic features. These are the prior things to be considered as primary analysis. Cancer is generally treated as the biggest threat in today’s world so all the industries are trying to improve the diagnostic methodology to reduce the cancer threats. In addition, provides a miniaturized way of treating the patients. Download a free sample cancer diagnostics market  pdf @ https://www.envisioninteligence.com/industry-report/global-cancer-diagnostics-market/ Biopsy and Imaging segments held the largest revenue shares in cancer diagnostics market and the trend is expected to continue during the forecast period. Biopsy segment valued at more than $XX billion in 2016. It is expected to register a tremendous Y-o-Y growth throughout the forecast period owing to its non-invasive nature as well as to obtain an accurate diagnosis. Imaging segment is having the largest revenue share in 2016, trend is expected to continue to over the forecast time owing to wide range of applicability of imaging devices to detect majority of cancer types coupled with the introduction of advanced cancer diagnostics types by technology including MRI, CT, PET and others will positively impact cancer diagnostics market growth. According to the Cancer diagnostics market research, Breast cancer diagnostics market segments accounted for the largest share in 2016 Cancer diagnostics market is segmented into breast cancer, lung cancer, prostrate cancer, blood cancer, cervical cancer, kidney cancer and others based on application among which breast cancer is accounted for the major share in the market. The women mainly above the age of 40 are recommended to undergo mammography every 2 years as the women aged between 50 to 74 are at a higher risk of developing breast cancer. Hence, breast cancer is accounted for the largest share in the market owing to the prevalence of cancer in the aging population and also helps to boost the global cancer diagnostics tests market. Moreover, lung cancer is expected to show a brisk growth during the forecast period which will raise the demand for the lung cancer diagnostic market. North America dominated the global cancer diagnostics market by capturing largest revenue share in 2016. North America dominated the global cancer diagnostics market by size in 2016 owing to well-developed technology, increasing patient pool with cancer, high health care spending, and increasing government support for research & development. Furthermore, increased R&D activities, due to developed healthcare infrastructure, government initiatives towards public health care that are expected to drive this dominance and the concentration of major companies have fuelled the growth of the market in this region. Asia – Pacific region is expected to show highest CAGR during the forecast period and also generates huge revenue to the vendors operating in this region owing increasing aging population and increasing cancer cases in India which will propel the growth of the cancer diagnostics market in India. Major players in the market are: Agilent Technologies, Inc. Abbott Laboratories, Inc GE Healthcare Qiagen N.V Roche Diagnostics Siemens Healthcare Becton Dickson and Company Thermo Fisher Scientific Inc